

Eli L Diamond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/218304/publications.pdf>

Version: 2024-02-01

78
papers

6,784
citations

136950

32
h-index

76900

74
g-index

81
all docs

81
docs citations

81
times ranked

7524
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.	1.2	6
2	ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. <i>Blood</i> , 2022, 139, 256-280.	1.4	60
3	Rosai-Dorfman disease of the nervous system: a systematic literature review. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 92.	2.7	6
4	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. <i>Blood</i> , 2022, 139, 2601-2621.	1.4	63
5	Progressive nodular histiocytosis in a 9-year-old boy treated with cobimetinib. <i>Pediatric Dermatology</i> , 2022, 39, 115-118.	0.9	3
6	Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. <i>Journal of Neuro-Oncology</i> , 2022, 158, 69-79.	2.9	7
7	18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1154-1165.	6.4	10
8	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. <i>Neurology</i> , 2021, 96, 1091-1093.	1.1	3
9	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	1.2	33
10	Ethics consultations in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2021, 8, 539-549.	1.6	2
11	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2021, 5, 1187-1195.	2.4	5
12	Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa159.	0.7	7
13	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1277-1303.	4.9	26
14	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. <i>Leukemia</i> , 2021, , .	7.2	3
15	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
16	MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. <i>Ocular Oncology and Pathology</i> , 2020, 6, 159-163.	1.0	8
17	The coming of age of Langerhans cell histiocytosis. <i>Nature Immunology</i> , 2020, 21, 1-7.	14.5	34
18	Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocytosis and recent dabrafenib treatment. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100868.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Palliative Care in High-Grade Glioma: A Review. <i>Brain Sciences</i> , 2020, 10, 723.	2.3	18
20	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. <i>Cancers</i> , 2020, 12, 3240.	3.7	5
21	Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e686.	6.0	2
22	Rosai-Dorfman Disease—Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. <i>Clinical Nuclear Medicine</i> , 2020, 45, e260-e266.	1.3	22
23	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	9.4	93
24	The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 1406-1417.	1.3	8
25	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
26	Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa024.	0.7	7
27	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. <i>Blood</i> , 2020, 135, 1929-1945.	1.4	191
28	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
29	Cobimetinib-induced “dropped head syndrome” and subsequent disease management in an Erdheim-Chester patient. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1989-1993.	0.5	6
30	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1149-1157.	4.1	26
31	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	27.8	222
32	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. <i>Blood Advances</i> , 2019, 3, 934-938.	5.2	17
33	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
34	Single-agent dabrafenib for <i>BRAF</i> ^{V600E} -mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	3.5	40
35	Associations between Mild Cognitive Dysfunction and End-of-Life Outcomes in Patients with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2018, 21, 536-540.	1.1	3
36	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Desombes disease. <i>Blood</i> , 2018, 131, 2877-2890.	1.4	335

#	ARTICLE	IF	CITATIONS
37	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26699.	1.5	16
38	Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26784.	1.5	59
39	Vemurafenib for <i>BRAF</i> V600E Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	7.1	280
40	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. <i>Modern Pathology</i> , 2018, 31, 581-597.	5.5	102
41	Erdheim-Chester Disease. , 2018, , 313-338.		2
42	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	1.6	39
43	Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma". <i>World Neurosurgery</i> , 2018, 117, 466.	1.3	2
44	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	8.2	45
45	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018, 132, 49-49.	1.4	10
46	The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease. <i>Blood</i> , 2018, 132, 2397-2397.	1.4	1
47	Frequency and Risk Factors for Live Discharge from Hospice. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1726-1732.	2.6	42
48	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. <i>Blood</i> , 2017, 130, 167-175.	1.4	136
49	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	1.4	98
50	Erdheim-Chester disease: the "targeted" revolution. <i>Blood</i> , 2017, 130, 1282-1284.	1.4	12
51	Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. <i>Neuro-Oncology</i> , 2017, 19, 1532-1541.	1.2	51
52	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	1.4	98
53	Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 257-264.	1.2	20
54	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Histiocytic neoplasms in the era of personalized genomic medicine. <i>Current Opinion in Hematology</i> , 2016, 23, 416-425.	2.5	37
56	Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas. <i>Journal of Neuroimaging</i> , 2016, 26, 366-371.	2.0	25
57	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016, 127, 2672-2681.	1.4	1,040
58	Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. <i>Blood</i> , 2016, 128, 1896-1898.	1.4	24
59	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 109.	2.7	19
60	Rates and risks for late referral to hospice in patients with primary malignant brain tumors. <i>Neuro-Oncology</i> , 2016, 18, 78-86.	1.2	69
61	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
62	Existential distress among caregivers of patients with brain tumors: a review of the literature. <i>Neuro-Oncology Practice</i> , 2016, 3, 232-244.	1.6	44
63	High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. <i>Leukemia and Lymphoma</i> , 2016, 57, 1961-1964.	1.3	7
64	Nonenhancing Leptomeningeal Metastases. <i>Neurohospitalist, The</i> , 2016, 6, 24-28.	0.8	19
65	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016, 7, 85430-85436.	1.8	60
66	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma". <i>Acta Neuropathologica</i> , 2015, 129, 151-153.	7.7	87
67	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	27.0	1,483
68	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	9.4	115
69	Temporal Lobe Meningioma With Ipsilateral Herpes Simplex Encephalitis. <i>Neurohospitalist, The</i> , 2014, 4, 42-43.	0.8	0
70	Giant cell arteritis presenting with bilateral orbital inflammatory disease and enhancing superficial temporal arteries. <i>Practical Neurology</i> , 2014, 14, 446-447.	1.1	11
71	Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review. <i>Journal of Neuro-Oncology</i> , 2014, 119, 227-234.	2.9	41
72	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	1.4	462

#	ARTICLE	IF	CITATIONS
73	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	1.4	197
74	Visualization of Orbital Involvement of Erdheim-Chester Disease on PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 660-661.	1.3	4
75	Minor Cognitive Impairments in Cancer Patients Magnify the Effect of Caregiver Preferences on End-of-Life Care. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 650-659.	1.2	23
76	Detection of an NRAS mutation in Erdheim-Chester disease. <i>Blood</i> , 2013, 122, 1089-1091.	1.4	57
77	Transient aqueductal occlusion in intracerebral haemorrhage. <i>Practical Neurology</i> , 2012, 12, 388-389.	1.1	3
78	A Population-Based Study of Treatment and Survival in Older Glioma Patients. <i>JNCI Cancer Spectrum</i> , 0, ,.	2.9	4